Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus | Zendy

Anjum S. Kaka | Zendy; Adriana M. Rueda | Zendy; Samuel A. Shelburne | Zendy; Kristina G. Hultén | Zendy; Richard J. Hamill | Zendy; Daniel M. Musher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus

Author(s) -

Anjum S. Kaka,

Adriana M. Rueda,

Samuel A. Shelburne,

Kristina G. Hultén,

Richard J. Hamill,

Daniel M. Musher

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl283

Subject(s) - trimethoprim , linezolid , antimicrobial , sulfamethoxazole , microbiology and biotechnology , clindamycin , staphylococcus aureus , methicillin resistant staphylococcus aureus , antibiotics , rifampicin , medicine , moxifloxacin , biology , vancomycin , bacteria , genetics

The recent proliferation of community-acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) has led to a marked increase in the need for outpatient treatment of MRSA infections. Many oral agents active against MRSA have been available for years, and a paucity of literature compares them, leaving physicians with little guidance for choosing among them. The purpose of the present study was to compare the bactericidal effects of orally available antibiotics against MRSA and to determine whether there were differences in antimicrobial killing activity against CA-MRSA and hospital-acquired (HA) MRSA isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research